These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 12122161

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Neutralising antibodies against interferon beta in multiple sclerosis.
    Antonelli G.
    Lancet; 2004 Jan 10; 363(9403):168; author reply 168-9. PubMed ID: 14726180
    [No Abstract] [Full Text] [Related]

  • 3. Neutralising antibodies against interferon beta in multiple sclerosis.
    Mikol D.
    Lancet; 2004 Jan 10; 363(9403):167-8; author reply 168-9. PubMed ID: 14726179
    [No Abstract] [Full Text] [Related]

  • 4. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis.
    Polman CH, Kappos L, Petkau J, Thompson A.
    J Neurol Neurosurg Psychiatry; 2003 Aug 10; 74(8):1162; author reply 1162-3. PubMed ID: 12876268
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neutralising antibodies against interferon beta in multiple sclerosis.
    Giovannoni G, Deisenhammer F.
    Lancet; 2004 Jan 10; 363(9403):166-7; author reply 168-9. PubMed ID: 14726177
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta.
    Mayorga C, Luque G, Romero F, Guerrero R, Blanca M, Fernandez O.
    Int Arch Allergy Immunol; 1999 Jan 10; 118(2-4):368-71. PubMed ID: 10224450
    [No Abstract] [Full Text] [Related]

  • 12. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.
    Hemmer B, Stüve O, Kieseier B, Schellekens H, Hartung HP.
    Lancet Neurol; 2005 Jul 10; 4(7):403-12. PubMed ID: 15963443
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
    Horowski R, Stürzebecher CS, Kapp JF.
    Funct Neurol; 2001 Jul 10; 16(2):117-28. PubMed ID: 11495417
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Beta-interferon neutralizing antibodies. Do they have clinical value in patients with multiple sclerosis?].
    Romero López J, Maciñeiras Montero JL.
    Med Clin (Barc); 2005 Feb 05; 124(4):144-5. PubMed ID: 15713245
    [No Abstract] [Full Text] [Related]

  • 17. Comments on the report of the EFNS task force on IFN-beta antibodies in multiple sclerosis.
    Freedman MS.
    Eur J Neurol; 2007 Jun 05; 14(6):e7; author reply e10-1. PubMed ID: 17539930
    [No Abstract] [Full Text] [Related]

  • 18. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, Milano E, Melis F, Giordana MT.
    J Neurol Neurosurg Psychiatry; 2002 Aug 05; 73(2):148-53. PubMed ID: 12122172
    [Abstract] [Full Text] [Related]

  • 19. Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies.
    Mayr M, Berek K, Deisenhammer F.
    Eur J Neurol; 2003 Jul 05; 10(4):462-4. PubMed ID: 12823504
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.